Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

XTX Markets announces launch of new machine learning division ‘XTY Labs’ headed by Dr. Atlas Wang




LONDON, Feb. 22, 2024 /PRNewswire/ — XTX Markets, a leading algorithmic trading company, is excited to announce the launch of XTY Labs, a new machine learning division to be headed by newly appointed Research Director, Dr. Atlas Wang.

XTY Labs is set to become a hub for elite machine learning researchers and will be home to the new ‘XTY Labs AI Residency Program’, offering researchers short-term AI residency contracts ranging from 6-12 months.

For more details on the program and AI residencies (in terms of the roles and compensation) click here.

The program is designed to provide elite researchers with the freedom, guidance and resources to create cutting-edge machine learning solutions tailored for the complexities of finance.

Award-winning, machine learning specialist Dr. Atlas Wang will lead XTY Labs. He brings a wealth of experience and extensive expertise in machine learning, optimization and AI technologies to the role.

Dr. Atlas Wang, Research Director of XTX Markets’ XTY Labs, commented:

“I am thrilled to join XTX Markets. It’s an honour to lead such a unique division where the brightest minds in AI and finance will converge to redefine the future of algorithmic trading. Our mission is to rapidly turn the latest AI breakthroughs into tangible market advantages, and I eagerly anticipate the revolutionary solutions that will emerge from this truly unique endeavour.

With a world-class team, unparalleled resources, and a culture that fosters pioneering research, the XTY Labs is poised to become the crucible of next-generation financial technologies.”

Dr. Alex Gerko, Founder and Co-CEO of XTX Markets, commented:

“We are delighted to launch XTY Labs and welcome Atlas to the team. This launch is a response to the many queries we have had from exceptional candidates, who may not be ready to take the leap into finance full time.

The program is designed to match the experience of XTX researchers as closely as possible and it’s a fantastic opportunity for some to eventually transition into the core quant team at XTX.

We look forward to supporting and nurturing the AI residents and seeing the developments from XTY Labs in the coming years.”

About XTX Markets, XTY Labs and the AI Residency Program:

XTX Markets is a leading algorithmic trading company and has over 200 employees based in London, Paris, New York, Mumbai, Yerevan and Singapore. XTX provides liquidity in the Equity, FX, Fixed Income and Commodity markets and trades over $250bn a day across markets.

XTX Markets’ expansive research cluster contains 100,000 cores and 20,000 A/V100 GPUs and is growing.  We also have 390 petabytes of usable storage and 7.5 petabytes of RAM.

Alongside rich datasets and advanced technological infrastructure we are at the forefront of the crossover of finance and technology.

XTX’s corporate philanthropy focuses on STEM education and maximum impact giving (alongside an employee matching programme). Since 2017, XTX has donated over £100mn to charities and good causes, establishing it as a major donor in the UK and globally.

XTY Labs is designed to be a home for those eager to pioneer the future of algorithmic trading, with a strategic focus on developing and applying novel machine learning techniques to financial data.

The division will be situated in Hudson Yards (New York) where researchers will have the opportunity to explore new ideas and transform their advanced machine learning research into real-world financial solutions, backed by XTX Markets’ expansive research cluster containing 100,000 cores and 20,000 A/V100 GPUs and growing, alongside rich datasets, and advanced technological infrastructure.

Emphasizing practical application, the Lab’s mission is to swiftly integrate successful models into the market, directly enhancing XTX Market’s trading strategies and operations. This direct pipeline from research to implementation establishes the XTY Labs as a premier destination for those looking to make a significant impact in the financial sector through original machine learning research.

XTY Labs is seeking AI Residents with a history of significant contributions to research in elite academic settings, such as PhDs, post-docs, or professorships to join the XTY Labs AI Residency Program. Exceptional machine learning researchers looking to explore how their expertise can revolutionize the finance industry will find fertile ground for research breakthroughs at the intersection of AI and finance within the XTY Labs.

There are two pathways within the AI Resident Program, designed to accommodate professionals at varying stages of their research careers, with both Junior and Senior AI residencies, each tailored to align with the applicants’ research experience and expertise.

Top-performers from the program will have the opportunity to transition into the core quantitative team of XTX Markets in London.

About Dr. Atlas Wang:

Dr. Atlas Wang has been a tenured Associate Professor at The University of Texas at Austin and has held various industry roles, most recently appointed as the new Research Director at XTX Markets. Dr. Wang, with a distinguished academic and professional track record, brings extensive expertise in machine learning, optimization, and AI technologies.

His research focuses on efficiently training and scaling foundational models, model robustness, and generative AI, among other areas.

Dr. Wang has received numerous awards, including the IEEE AI’s 10 To Watch Award, an NSF CAREER Award, an ARO Young Investigator Award, and many other accolades from industry and professional societies.


View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading